Teva Pharmaceutical Industries Limited (TEVA)

From the record

Teva Pharmaceutical Industries Limited's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Teva Pharmaceutical Industries Limited's 10 filed years say what it did: revenue went from $22 billion in fiscal 2016 to $17 billion in fiscal 2025, down 2.6% a year; it rose in 3 of 9 years; the deepest fall was 32% from fiscal 2016 to fiscal 2022; net income was positive in 3 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Teva Pharmaceutical Industries Limited's diluted share count grew about 1.6% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 66 sales (32 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-12 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Teva Pharmaceutical Industries Limited earned about 18 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 22 cents per dollar of everything the company owns. Leverage: it owed about 81 cents per dollar of assets, and net share issuance: its share count grew 2.8% over the year (the filed statements).

From the record

Teva Pharmaceutical Industries Limited's standing among 315 graded names in its industry family: revenue of $17 billion in fiscal 2025 ranks in the top 3% by size; a net margin of 8.2% ranks in the top 18%; revenue growth of 5% a year over the last 3 filed years ranks in the bottom 46% (its annual reports).

From the record

Teva Pharmaceutical Industries Limited's leadership, from its insiders' filings and its current reports: the chief executive on the record is Francis, Richard D (President and CEO, as filed), filing under that title since 2023-01-03, 3.9 years (bottom 41% of its family); the 23 officers and directors filing in the last fifteen months have been on the record a median of 4.9 years (bottom 35%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 23 people in charge now (top 9%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Teva Pharmaceutical Industries Limited's room to grow, from the newest filed statements (fiscal 2025): cash of $3.6 billion against no long-term debt tagged leaves 8.7% of its assets as net cash, bottom 24% of its family; cash from operations less capital spending is 6.7% of revenue (top 24%); a gross margin of 51.8% (bottom 27%); research spending of 5.9% of revenue (bottom 6%) (its annual report).

From the record

Teva Pharmaceutical Industries Limited's growth drivers, from the filed years to fiscal 2025: revenue grew 5% a year over the last three filed years against -2.6% over all 10, speeding up (top 20% of its family); the newest year grew 4.3% (bottom 45%); research spending grew 6.5% a year (top 44%); capital spending grew -2.9% a year (top 41%) (its annual reports). Teva Pharmaceutical Industries Limited reported 4 lines of business in fiscal 2025: United States at $9.2 billion (53%), Europe at $5.0 billion (29%), International Markets at $2.2 billion (13%), and 1 more; 1 of 4 grew against the year before (its annual report).

From the record

Teva Pharmaceutical Industries Limited's newest year against its own record: revenue of $17 billion in fiscal 2025 came in 0.9% below the $17 billion its prior three years' pace pointed to (top 48% of its family); net income of $1.4 billion against a prior three-year average of $1.5 billion (top 7%); a net margin of 8.2% against -9.9% before (top 45%) (its annual reports).